Free Trial
NASDAQ:CRVO

CervoMed Q1 2024 Earnings Report

CervoMed logo
$9.46 +0.15 (+1.56%)
As of 10:44 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

CervoMed EPS Results

Actual EPS
-$0.41
Consensus EPS
-$0.46
Beat/Miss
Beat by +$0.05
One Year Ago EPS
N/A

CervoMed Revenue Results

Actual Revenue
$2.35 million
Expected Revenue
$2.00 million
Beat/Miss
Beat by +$350.00 thousand
YoY Revenue Growth
N/A

CervoMed Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Tuesday, May 14, 2024
Conference Call Time
6:00PM ET

Upcoming Earnings

CervoMed's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Wednesday, November 12, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

CervoMed Earnings Headlines

Research Analysts Set Expectations for CervoMed Q3 Earnings
Missed the Last 10,000% Surge? Here’s Your Next Chance
Axcelis Technologies went from $2.50 to $180—a staggering 7,100% return. These are the kinds of small-cap breakouts Fierce Analyst aims to catch before they go mainstream. Our research team uses data and trend analysis to uncover high-potential stocks early. And now, you can get free alerts on the next set of breakout candidates—before the crowd rushes in.tc pixel
See More CervoMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like CervoMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CervoMed and other key companies, straight to your email.

About CervoMed

CervoMed (NASDAQ:CRVO), a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

View CervoMed Profile

More Earnings Resources from MarketBeat